Diabetes and Hypertension: Epidemiology of the Relationship and Pathophysiology of Factors Associated With These Comorbid Conditions
Mark H. Schutta MD,
Mark H. Schutta MD
From the Rodebaugh Diabetes Center, Hospital of the University of Pennsylvania, Philadelphia, PA
Search for more papers by this authorMark H. Schutta MD,
Mark H. Schutta MD
From the Rodebaugh Diabetes Center, Hospital of the University of Pennsylvania, Philadelphia, PA
Search for more papers by this authorMark H. Schutta, MD, Hospital of the University of Pennsylvania, Rodebaugh Diabetes Center, 4 Penn Tower, 3400 Spruce Street, Philadelphia, PA 19104 E-mail: [email protected]
Abstract
Diabetes and hypertension frequently coexist, leading to additive increases in the risk of life-threatening cardiovascular events. Hypertension is a common comorbid condition in patients with type 1 or type 2 diabetes when compared with the general population and occurs in 75% of patients with the more prevalent form of diabetes, type 2. Arterial blood pressure plays an important role in the development of renal damage and presents a complex relationship. It is well-known that hypertension accelerates the course of microvascular and macrovascular complications of diabetes and that hypertension often precedes type 2 diabetes and vice versa. Patients with type 1 and 2 diabetes and nephropathy frequently have circadian changes in blood pressure that correlate to nephropathy risk. Early detection of nocturnal hypertension and early intervention with angiotensin blockade may delay progression of diabetic nephropathy.
References
- 1 International Diabetes Federation Web site. Facts & Figures: Diabetes Prevalence. Available at: http://www.idf.org/home/index.cfm?node=264. Accessed August 11, 2006.
- 2 Cowie CC, Rust KF, Byrd-Holt DD, et al. Prevalence of diabetes and impaired fasting glucose in adults in the US population. National Health and Nutrition Examination Survey 1999–2002. Diabetes Care. 2006; 29: 1263–1268.
- 3 King H, Aubert RE, Herman WH. Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. Diabetes Care. 1998; 21: 1414–1431.
- 4 Eknoyan G, Hostetter T, Bakris GL, et al. Proteinuria and other markers of chronic kidney disease: a position statement of the National Kidney Foundation (NKK) and the National Institutes of Diabetes and Digestive and Kidney Diseases (NIDDK). Am J Kidney Dis. 2003; 42: 617–622.
- 5
Collins AJ,
Kasiske B,
Herzog C, et al.
Excerpts from the United States Renal Data System 2001 Annual Data Report: atlas of end-stage renal disease in the United States.
Am J Kidney Dis. 2001; 38: S7–S247.
10.1053/ajkd.2001.28240 Google Scholar
- 6 Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension. 2001; 37: 1053–1059.
- 7 2003 European Society of Hypertension. European Society of Cardiology guidelines for the management of arterial hypertension. European Society of Hypertension. J Hypertens. 2003; 21: 1011–1053.
- 8 US Department of Health and Human Services (DHHS). National Center for Health Statistics. Second National Health and Nutrition Examination Survey, (NHANES II), 1976-1980. Hyattsville, MD: Centers for Disease Control and Prevention.
- 9 Marks JB, Raskin P. Cardiovascular risk in diabetes: a brief review. J Diabetes Complications. 2000; 14: 108–115.
- 10 Newton CA, Raskin P. Blood pressure control—effects on diabetic nephropathy progression: how low does blood pressure have to be? Curr Diab Rep. 2002; 2: 530–538.
- 11 Sowers JR. Insulin resistance and hypertension. Am J Physiol Heart Circ Physiol. 2004; 286: H1597–H1602.
- 12 Gress TW, Nieto FJ, Shahar E, et al. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med. 2000; 342: 905–912.
- 13 Sowers JR, Bakris GL. Antihypertensive therapy and the risk of type 2 diabetes mellitus. N Engl J Med. 2000; 342: 969–970.
- 14 Nathan DM, Lachin J, Cleary P, et al, for the Diabetes Control and Complications Trial. Epidemiology of diabetes interventions and complications research group. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med. 2003; 348: 2294–2303.
- 15 Wingard DL, Barrett-Connor E. Heart disease and diabetes. In: National Diabetes Group, ed. Diabetes in America. Washington, DC: National Institutes of Health Publication No. 95–1468. National Institutes of Health; 1995: 429–448.
- 16 Sowers JR, Epstein M. Diabetes mellitus and associated hypertension, vascular disease, and nephropathy: an update. Hypertension. 1995; 26(pt 1): 869–879.
- 17 Warram JH, Gearin G, Laffel L, et al. Effect of duration of type 1 diabetes on the prevalence of stages of diabetic nephropathy defined by urinary albumin/creatinine ratio. J Am Soc Nephrol. 1996; 7: 930–937.
- 18 Bakris GL, Williams M, Dworkin L, et al, for the National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis. 2000; 36: 646–661.
- 19 Mogensen CE, Hansen KW, Pedersen MM, et al. Renal factors influencing blood pressure threshold and choice of treatment in IDDM. Diabetes Care. 1991; 14(suppl 4): 13–26.
- 20 Arauz-Pacheco C, Parrott MA, Raskin P; American Diabetes Association. Treatment of hypertension in adults. Diabetes Care. 2003; 26: S80–S82.
- 21 Sharma AM, Wittchen HU, Kirch W, et al, for the HYDRA Study Group. High prevalence and poor control of hypertension in primary care: cross-sectional study. J Hypertens. 2004; 22: 479–486.
- 22 Pittrow D, Wittchen H, Kirch W. Hypertension and diabetes care among primary care doctors in Germany: results from an epidemiologic cross-sectional study. In: W Kirch, ed. Public Health in Europe. New York, NY: Springer; 2003: 203–218.
- 23 Sowers JR. Diabetes mellitus and cardiovascular disease in women. Arch Intern Med. 1998; 158: 617–621.
- 24 Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998; 339: 229–234.
- 25 Sowers JR. Recommendations for special populations: diabetes mellitus and the metabolic syndrome. Am J Hypertens. 2003; 16: 41S–45S.
- 26 Sowers JR, Haffner S. Treatment of cardiovascular and renal risk factors in the diabetic hypertensive. Hypertension. 2002; 40: 781–788.
- 27 Moore WV, Donaldson DL, Chonko AM, et al. Ambulatory blood pressure in type 1 diabetes mellitus: comparison to presence of incipient nephropathy in adolescents and young adults. Diabetes. 1992; 41: 1035–1041.
- 28 Lurbe A, Redon J, Pascual JN, et al. Altered blood pressure during sleep in normotensive subjects with type 1 diabetes. Hypertension. 1993; 21: 227–235.
- 29 Lurbe E, Redon J, Kesani A, et al. Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes. N Engl J Med. 2002; 347: 797–805.
- 30 Guntsche A, Saravi FD, Reynals EA, et al. Parental hypertension and 24 h-blood pressure in children prior to diabetic nephropathy. Pediatr Nephrol. 2002; 17: 157–164.
- 31 Norris K, Vaughn C. The role of renin-angiotensin-aldosterone system inhibition in chronic kidney disease. Expert Rev Cardiovasc Ther. 2003; 1: 51–63.
- 32 Cooper ME. Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy. Diabetologia. 2001; 44: 1957–1972.
- 33 Raij L. Workshop: hypertension and cardiovascular risk factors role of the angiotensin II-nitric oxide interaction. Hypertension. 2001; 37: 767–773.
- 34 Weigert C, Brodbeck K, Brosius FC III, et al. Evidence for a novel TGF-β-independent mechanism of fibronectin production in mesangial cells overexpressing glucose transporters. Diabetes. 2003; 52: 527–535.
- 35 Heilig CW, Concepcion LA, Riser BL, et al. Overexpression of glucose transporters in rat mesangial cells cultured in a normal glucose milieu mimics the diabetic phenotype. J Clin Invest. 1995; 96: 1802–1814.
- 36 Steinberg HO, Brechtel G, Johnson A, et al. Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent: a novel action of insulin to increase nitric oxide release. J Clin Invest. 1994; 94: 1172–1179.
- 37 Baron AD, Steinberg HO, Chaker H, et al. Insulin-mediated skeletal muscle vasodilation contributes to both insulin sensitivity and responsiveness in lean humans. J Clin Invest. 1995; 96: 786–792.
- 38 Wendt T, Tanji N, Guo J, et al. Glucose, glycation and RAGE: implications for amplification of cellular dysfunction in diabetic nephropathy. J Am Soc Nephrol. 2003; 14: 1383–1395.
- 39 Miyata T, Van Ypersele de Strihou C, Kurokawa D, et al. Alterations in non-enzymatic biochemistry in uremia: origin and significance of “carbonyl stress” in long-term uremic complications. Kidney Int. 1999; 55: 389–399.
- 40 Sebekova K, Schinzel R, Munch G, et al. Advanced glycation end-product levels in subtotally nephrectomized rats. Beneficial effects of angiotensin II receptor 1 antagonist losartan. Miner Electrolyte Metab. 1999; 25: 380–383.
- 41 Bohlender J, Franke S, Sommer M, et al. Advanced glycation end products: a possible link to angiotensin in an animal model. Ann N Y Acad Sci. 2005; 1043: 681–684.
- 42 Delafontaine P, Song YH, Li Y. Expression, regulation, and function of IGF-1, IGF-1R, and IGF-1 binding proteins in blood vessels. Arterioscler Thromb Vasc Biol. 2004; 24: 435–444.
- 43 Du J, Sperling LS, Marrero MB, et al. G-protein and tyrosine kinase receptor cross-talk in rat aortic smooth muscle cells: thrombin- and angiotensin II-induced tyrosine phosphorylation of insulin receptor substrate-1 and insulin-like growth factor 1 receptor. Biochem Biophys Res Commun. 1996; 218: 934–939.
- 44 Delafontaine P, Lou H, Alexander RW. Regulation of insulin-like growth factor I messenger RNA levels in vascular smooth muscle cells. Hypertension. 1991; 18: 742–747.
- 45 Walsh MF, Barazi M, Sowers JR. IGF-1 diminishes in vivo and in vitro vascular contractility: role of vascular nitric oxide. Endocrinology. 1996; 137: 1798–1803.
- 46 Frystyk J, Ledet T, Moller N, et al. Cardiovascular disease and insulin-like growth factor I. Circulation. 2002; 106: 893–895.
- 47 Kobayashi T, Kamata K. Short-term insulin treatment and aortic expressions of IGF-1 receptor and VEGF mRNA in diabetic rats. Am J Physiol Heart Circ Physiol. 2002; 283: H1761–H1768.
- 48 Lee TS, Saltsman KA, Ohashi H, et al. Activation of protein kinase C by elevation of glucose concentration: proposal for a mechanism in the development of diabetic vascular complications. Proc Natl Acad Sci U S A. 1989; 86: 5141–5145.
- 49 Murphy LJ, Ghahary A, Chakrabarti S. Insulin regulation of IGF-I expression in rat aorta. Diabetes. 1990; 39: 657–662.
- 50 Schneider DJ, Sobel BE. Augmentation of synthesis of plasminogen activator inhibitor type 1 by insulin and insulin-like growth factor type I: implications for vascular disease in hyperinsulinemic states. Proc Natl Acad Sci U S A. 1991; 88: 9959–9963.
- 51 Sobel BE. Coronary artery disease and fibrinolysis; from the blood to the vessel wall. Thromb Haemost. 1999; 82(suppl): 8–13.
- 52 Considine RV. Human leptin: an adipocyte hormone with weight-regulatory and endocrine functions. Semin Vasc Med. 2005; 5: 15–24.
- 53 Considine RV, Sinha MK, Heiman ML, et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med. 1996; 334: 292–295.
- 54 Margetic S, Gazzola C, Pegg GG, et al. Characterization of leptin binding in bovine kidney membranes. Domest Anim Endocrinol. 2002; 23: 411–424.
- 55 Aizawa-Abe M, Ogawa Y, Masuzaki H, et al. Pathophysiological role of leptin in obesity-related hypertension. J Clin Invest. 2000; 105: 1243–1252.
- 56 Considine RV. Human leptin: an adipocyte hormone with weight-regulatory and endocrine functions. Semin Vasc Med. 2005; 5: 15–24.
- 57 Shek EW, Brands MW, Hall JE. Chronic leptin infusion increases arterial pressure. Hypertension. 1998; 31(1 pt 2): 409–414.
- 58 Aizawa-Abe M, Ogawa Y, Masuzaki H, et al. Pathophysiological role of leptin in obesity-related hypertension. J Clin Invest. 2000; 105: 1243–1252.
- 59 Skurk T, van Harmelen V, Blum WF, et al. Angiotensin II promotes leptin production in cultured human fat cells by an ERK1/2-dependent pathway. Obes Res. 2005; 13: 969–973.
- 60 Schutte R, Huisman HW, Schutte AE, et al. Leptin is independently associated with systolic blood pressure, pulse pressure and arterial compliance in hypertensive African women with increased adiposity: the POWIRS study. J Hum Hypertens. 2005; 19: 535–541.
- 61 Beltowski J, Jamroz-Wisniewska A, Borkowska E, et al. Up-regulation of renal Na+, K+-ATPase: the possible novel mechanism of leptin-induced hypertension. Pol J Pharmacol. 2004; 56: 213–222.
- 62 Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. 2004; 89: 2548–2556.
- 63 Diep QN, Benkirane K, Amiri F, et al. PPARα activator fenofibrate inhibits myocardial inflammation and fibrosis in angiotensin II-infused rats. J Mol Cell Cardiol. 2004; 36: 295–304.
- 64 Touyz RM, Schiffrin EL. Peroxisome proliferator-activated receptors in vascular biologymolecular mechanisms and clinical implications. Vascul Pharmacol. 2006; 45: 19–28.
- 65 Iglarz M, Touyz RM, Amiri F, et al. Effect of peroxisome proliferator-activated receptor α and -γ activators on vascular remodeling in endothelin-dependent hypertension. Arterioscler Thromb Vasc Biol. 2003; 23: 45–51.
- 66 Touyz RM, Schiffrin EL. Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications. Vascul Pharmacol. 2006; 45: 19–28.
- 67 Lebovitz HE, Dole JF, Patwardhan R, et al, for the Rosiglitazone Clinical Trials Study Group. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab. 2001; 86: 280–288.
- 68 Lebovitz HE. Rationale for and role of thiazolidinediones in type 2 diabetes mellitus. Am J Cardiol. 2002; 90: 34G–41G.
- 69 Pershadsingh HA, Szollosi J, Benson S, et al. Effects of ciglitazone on blood pressure and intracellular calcium metabolism. Hypertension. 1993; 21: 1020–1023.
- 70 Ogihara T, Rakugi H, Ikegami H, et al. Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives. Am J Hypertens. 1995; 8: 316–320.
- 71 Winkler K, Konrad T, Fullert S, et al. Pioglitazone reduces atherogenic dense LDL particles in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study. Diabetes Care. 2003; 26: 2588–2594.
- 72 Grinsell JW, Lardinois CK, Swislocki A, et al. Pioglitazone attenuates basal and postprandial insulin concentrations and blood pressure in the spontaneously hypertensive rat. Am J Hypertens. 2000; 13(4 pt 1): 370–375.
- 73 Gerber P, Lubben G, Heusler S, et al. Effects of pioglitazone on metabolic control and blood pressure: a randomised study in patients with type 2 diabetes mellitus. Curr Med Res Opin. 2003; 19: 532–539.
- 74 Negro R, Dazzi D, Hassan H, et al. Pioglitazone reduces blood pressure in nondipping diabetic patients. Minerva Endocrinol. 2004; 29: 11–17.
